5:04 PM
 | 
Nov 07, 2012
 |  BC Extra  |  Clinical News

Depomed's DM-1992 meets Phase II Parkinson's endpoint

Depomed Inc. (NASDAQ:DEPO) said twice-daily DM-1992 met the primary endpoint vs. generic immediate-release (IR) carbidopa-levodopa dosed as needed (average of 4.8 doses/day) in a Phase II trial to treat Parkinson's disease (PD). DM-1992 significantly reduced...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >